Over 300 abnormal hemoglobins — such as sickle cell hemoglobin — have been discovered, most of which are either neutral or harmful to their carriers, and numerous thalassemias, which result ...

Pfizer PFE3.46%increase; green up pointing triangle said it is voluntarily withdrawing all lots of its sickle-cell drug Oxbryta in all markets where it is approved, two years after acquiring its ...

Buried around six-feet below the slab, they found three skeletons, one of which had a sickle around its neck, a medieval practice which - it was believed - was designed to stop vampires returning ...

Eric Boodman, a STAT general assignment reporter, is the author of a series about sickle cell disease and forced sterilizations. She knew what it was to have pain she couldn’t put into words ...

The EU's drug watchdog Thursday called for the suspension of approval for Pfizer's medicine to treat sickle cell disease, saying doctors should stop using the drug. The European Medicines Agency's ...

LOS ANGELES, Sept 28 (Reuters) - Student Zoe Davis, 20, was just weeks into her junior year when she landed back in the hospital with severe sickle cell pain earlier this month. She is doing what ...

Because sickle cell disease isn’t as progressive a disease as others that have gene therapies available, there isn’t as much urgency to start on these expensive therapies, said Kevin Niehoff ...

Pfizer’s startling announcement late Wednesday that it would pull its pill for sickle-cell disease off pharmacy shelves is a ...

Pfizer said Wednesday that it was removing Oxbryta, a pill for the treatment of sickle cell disease, from all markets globally due to high risks of severe safety events, including deaths.

Pfizer will voluntarily pull its sickle cell disease (SCD) drug Oxbryta from all markets worldwide, a major blow to a $5.4 billion acquisition the New York pharma made two years ago. Pfizer will ...

Pfizer (NYSE:PFE) has voluntarily withdrawn all lots of its sickle cell disease drug Oxbryta, also known as voxelotor, over safety concerns. The pharmaceutical giant said Oxbryta will be withdrawn ...

Sept 26 (Reuters) - U.S. drugmaker Pfizer (PFE.N), opens new tab said on Wednesday it was withdrawing its sickle cell disease treatment Oxbryta from all markets where it is approved, citing risks ...